Literature DB >> 17369837

CD8(+) T-cell responses to adeno-associated virus capsid in humans.

Federico Mingozzi1, Marcela V Maus, Daniel J Hui, Denise E Sabatino, Samuel L Murphy, John E J Rasko, Margaret V Ragni, Catherine S Manno, Jurg Sommer, Haiyan Jiang, Glenn F Pierce, Hildegund C J Ertl, Katherine A High.   

Abstract

Hepatic adeno-associated virus (AAV)-serotype 2 mediated gene transfer results in transgene product expression that is sustained in experimental animals but not in human subjects. We hypothesize that this is caused by rejection of transduced hepatocytes by AAV capsid-specific memory CD8(+) T cells reactivated by AAV vectors. Here we show that healthy subjects carry AAV capsid-specific CD8(+) T cells and that AAV-mediated gene transfer results in their expansion. No such expansion occurs in mice after AAV-mediated gene transfer. In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17369837     DOI: 10.1038/nm1549

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  306 in total

1.  Dystrophin immunity in Duchenne's muscular dystrophy.

Authors:  Jerry R Mendell; Katherine Campbell; Louise Rodino-Klapac; Zarife Sahenk; Chris Shilling; Sarah Lewis; Dawn Bowles; Steven Gray; Chengwen Li; Gloria Galloway; Vinod Malik; Brian Coley; K Reed Clark; Juan Li; Xiao Xiao; Jade Samulski; Scott W McPhee; R Jude Samulski; Christopher M Walker
Journal:  N Engl J Med       Date:  2010-10-07       Impact factor: 91.245

Review 2.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

3.  Cell phones and landlines: the impact of gene therapy on the cost and availability of treatment for hemophilia.

Authors:  Katherine A High; Mark W Skinner
Journal:  Mol Ther       Date:  2011-10       Impact factor: 11.454

4.  Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness.

Authors:  Defne Amado; Federico Mingozzi; Daniel Hui; Jeannette L Bennicelli; Zhangyong Wei; Yifeng Chen; Erin Bote; Rebecca L Grant; Jeffrey A Golden; Kristina Narfstrom; Nasreen A Syed; Stephen E Orlin; Katherine A High; Albert M Maguire; Jean Bennett
Journal:  Sci Transl Med       Date:  2010-03-03       Impact factor: 17.956

5.  AAV provides an alternative for gene therapy of the peripheral sensory nervous system.

Authors:  Andreas S Beutler
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

6.  Hepatic AAV gene transfer and the immune system: friends or foes?

Authors:  Roland W Herzog
Journal:  Mol Ther       Date:  2010-06       Impact factor: 11.454

Review 7.  Antigen-presenting cell function in the tolerogenic liver environment.

Authors:  Angus W Thomson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-11       Impact factor: 53.106

Review 8.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

9.  Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

Authors:  Lindsey A George; Spencer K Sullivan; Adam Giermasz; John E J Rasko; Benjamin J Samelson-Jones; Jonathan Ducore; Adam Cuker; Lisa M Sullivan; Suvankar Majumdar; Jerome Teitel; Catherine E McGuinn; Margaret V Ragni; Alvin Y Luk; Daniel Hui; J Fraser Wright; Yifeng Chen; Yun Liu; Katie Wachtel; Angela Winters; Stefan Tiefenbacher; Valder R Arruda; Johannes C M van der Loo; Olga Zelenaia; Daniel Takefman; Marcus E Carr; Linda B Couto; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

10.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.